Elanco discloses FDA submission for JAK inhibitor at JPM conference

Elanco Animal Health Inc

Company notes Q4 2022 submission to FDA for its JAK inhibitor.
Presentation made at 41st Annual J.P. Morgan Healthcare Conference on Jan 10, 2023.
No financial results or guidance changes provided in the filing.

item 7.01 item 9.01

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-002071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.